Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
52W High
$30.36
52W Low
$8.93
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.38
Valuation
Rich
As of 2023-12-31 (Overview)
Trailing P/E (<15 better)
173.44
Forward P/E (<15 better)
77.52
EV/EBITDA (<8 favorable)
113.13
EV/Revenue (<3 favorable)
12.96
P/S (TTM) (<3 favorable)
8.09
P/B (<3 favorable)
20.71
Ownership
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.00%
Shares Outstanding
334,724,000
Float
282,349,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2023-12-31 (Overview)
Revenue (TTM)
645,677,000
Gross Profit (TTM)
405,348,000
EPS (TTM)
0.09
Profit Margin (>10% good)
0.08%
Operating Margin (TTM) (higher better)
0.09%
ROE (TTM) (>15% strong)
0.21%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.58
Momentum
Bearish momentumValue
-1.1372
Previous
-1.1701
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025